Wegovy injections for weight loss
Wegovy (semaglutide) is a prescription-only, once-weekly injection for weight management in adults, used alongside a reduced-calorie diet and more activity.2
From £119 a month
Check your eligibility →- CQC registered
- UK-registered clinicians
- Plain, discreet delivery
All content on this page has been medically reviewed by Naeem Teni, Clinical Lead. GPhC 2215591.
What is Wegovy?
Wegovy (semaglutide) is a prescription-only, once-weekly injection for weight management in adults, used alongside a reduced-calorie diet and more activity.2
A clinician reviews your assessment before anything is prescribed, and is there if you have questions along the way.
How does Wegovy work?
- It mimics a gut hormone. Semaglutide works like GLP-1, a hormone your gut releases after eating that tells your brain you've had enough.2
- Hunger turns down. For many people that means less hunger between meals and feeling full sooner, so eating less takes less effort.
- Digestion slows. It slows how quickly your stomach empties, so food stays with you longer and portions start to feel smaller on their own.
- Your changes do the rest. It supports changes to how you eat and move rather than replacing them. When treatment stopped in trials, much of the weight tended to return.3
How much weight can I lose with Wegovy?
average weight loss at the 2.4mg dose over 68 weeks, vs 2.4% on placebo1
14.9% average weight loss on Wegovy, vs 2.4% on placebo.1
Share of people on Wegovy who lost…
STEP 1, 1,961 adults. On placebo: 31.5%, 12.0% and 4.9%. Results vary from person to person.1
What is the dosing schedule for Wegovy?
You start at 0.25mg and step up every 4 weeks, only if it suits you. Each price is a month of four weekly doses.
Prices include your treatment and the care around it. Plenty of people stay on a lower dose.
Check your eligibility →
How do I use Wegovy?
- Pick your day. Inject on the same day each week, at any time, with or without food.2
- Choose a spot. Your stomach, thigh, or upper arm. Use a different spot each week.
- Inject. Follow the leaflet for your pen step by step. Your clinician can talk you through the first one.
- Store it right. Keep pens in the fridge at 2–8°C and never freeze them. Your pen's leaflet says how long it can be kept out of the fridge.
Missed a dose? If it's within 5 days, take it as soon as you remember. If it's been longer, skip it and take your next one on your usual day.2
How does Wegovy compare with other options?
Figures are average weight loss at the highest dose in each medicine's main trial, alongside diet and activity. They come from different trials in different people, so they aren't a direct ranking. The one direct comparison: when tirzepatide (Mounjaro) and injected semaglutide (Wegovy) were tested head to head over 72 weeks, average weight loss was 20.2% and 13.7%.7
| Wegovy | Mounjaro | Wegovy Pill | Foundayo | |
|---|---|---|---|---|
| Type | Semaglutide · Weekly injection | Tirzepatide · Weekly injection | Semaglutide · Daily tablet | Orforglipron · Daily tablet |
| Average weight loss in main trial | 14.9% over 68 weeks1 | 20.9% over 72 weeks4 | 13.6% over 64 weeks5 | 11.2% over 72 weeks6 |
| Key points | Acts on GLP-1 Same day each week | Acts on GIP and GLP-1 Same day each week | Acts on GLP-1 On an empty stomach with a sip of water, 30 minutes before food | Acts on GLP-1 Any time of day, with or without food |
| Price | £119 a month | £149 a month | £99 a month | See pricing |
| This page | View Mounjaro → | View Wegovy Pill → | View Foundayo → |
Is Wegovy right for me?
It isn't suitable for everyone. Your assessment covers all of this, and a clinician checks your answers before anything is prescribed.
Usually suitable if
- You're an adult, 18 or over, living in the UK.
- Your BMI is 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes.2
- You're ready to use it alongside changes to how you eat and move.
- A clinician judges it safe with your health history and medicines.
Not suitable if
- You're pregnant, planning a pregnancy, or breastfeeding.
- You have a history of medullary thyroid cancer or MEN 2.
- You're allergic to semaglutide or any of its ingredients.
- You have certain conditions, such as severe gastrointestinal disease.
Quick check
What's my BMI?
BMI is only a guide. A clinician looks at your whole health history.
What are the side effects of Wegovy?
Most side effects are mild, happen early on or after a dose increase, and ease with time. Your clinician is there if they don't.2
More common
Usually mild and short-lived
Rare
Get help straight away if
- Severe stomach pain that won't go away, sometimes reaching your back.
- Pain in the upper right of your stomach, fever, or yellowing skin or eyes.
- Vomiting or diarrhoea that stops you keeping fluids down.
- Swelling of your face, lips or throat, or trouble breathing.
Planning a pregnancy? Stop Wegovy at least 2 months before trying to conceive, as it takes time to leave your body.2
Wegovy FAQs
Is Manova a proper clinic, or a website?
Will it turn up in a branded box at my office?
What if the clinician says no?
Am I locked into a contract?
How is this different from going to my GP?
Read up on Wegovy
References (7)
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Wegovy (semaglutide) Summary of Product Characteristics. Novo Nordisk Ltd. Electronic Medicines Compendium (EMC).
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.